Loading…
Loading…
ALGEF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALGEF and 80,000+ other tickers.
See exactly how ALGEF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALGEF and 80,000+ other tickers.
Alligator Energy Limited, an Australian company, specializes in mineral exploration across both Australia and Italy. Its primary focus lies in discovering deposits of uranium, nickel, cobalt, and copper, alongside other critical energy minerals. The company's diverse portfolio includes key projects such as the Alligator Rivers Uranium Project in Australia's Northern Territory, the Samphire and Big Lake Uranium Projects located in South Australia, and the Piedmont project situated in Northern Italy. Furthermore, Alligator Energy maintains a strategic alliance with Traxys North America LLC…
Australian shares are set to open slightly lower, with ASX 200 futures pointing down 5 points or 0.1% to 8530 at around 7.30am AEDT, after recovering from...
Hazer Group Ltd (ASX:HZR, OTC:HZRGF) has entered into a non-binding memorandum of understanding (MoU) and graphite offtake letter of intent (LOI) with Green...
Alligator Energy Ltd (ASX:AGE, OTC:ALGEF) has reshaped its board, appointing chief executive officer Dr Andrea Marsland-Smith as managing director with...
Lamborghini and Rolls-Royce both face pressure from US import taxes and a stalling electric vehicle pivot, but their responses differ markedly Two of the...
Imugene Ltd (ASX:IMU, OTC:IUGNF) has reported another uplift in efficacy data from its Phase 1b trial of azer-cel, its allogeneic, off-the-shelf CD19 CAR-T...